Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triheptanoin in Long-Chain Fatty Acid Oxidation Disorders
NCT01379625Phase 2Completed
- Sponsor
- Oregon Health & Science University
- Start
- Sep 2011
- Primary completion
- Apr 2015
- Modality
- SLNs, Nanostructured Lipid Carriers, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of triheptanoin in very long-chain acyl-CoA dehydrogenase deficiency, carnitine palmitoyltransferase II deficiency, mitochondrial trifunctional protein deficiency (TFPD), long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency, sponsored by Oregon Health & Science University. Started Sep 2011; status: completed.
02
Drugs
triheptanoin
03
Conditions
very long-chain acyl-CoA dehydrogenase deficiencycarnitine palmitoyltransferase II deficiencymitochondrial trifunctional protein deficiency (TFPD)long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency
Beyond the preview
Go deeper on NCT01379625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01379625.